Department of Medicine Evaluation, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Acta Pharmacol Sin. 2011 Oct;32(10):1215-24. doi: 10.1038/aps.2011.83. Epub 2011 Aug 22.
To investigate possible pharmacological mechanisms underlying the antinociceptive effect of and tolerance to N-methyl-7α-[(R)-1-hydroxy-1-methyl-3-(thien-3-yl)-propyl]-6,14-endo-ethanotetrahydronororipavine (030418), a derivative of thienorphine.
The binding affinity and efficacy of 030418 were determined using receptor binding and guanosine 5'-O-(3-[(35)S]thio)triphosphate ([(35)S]GTPγS) assays in CHO-μ, CHO-κ, CHO-δ, and CHO-ORL1 cell membranes. The analgesic activity of and tolerance to 030418 were evaluated in thermal nociceptive tests in mice. The effects of 030418 on opioid receptors were further investigated using in vivo pharmacological antagonist blockade and in vitro tissue preparations.
The compound 030418 displayed high binding affinity to all subtypes of opioid receptors with K(i) values in the nanomolar range. In [(35)S]GTPγS binding assay, the maximal stimulation of 030418 to μ-, κ-, δ-receptors and the ORL1 receptor was 89%, 86%, 67% and 91%, respectively. In hot-plate test, the antinociceptive effect of 030418 was more potent and longer than morphine. The nonselective opioid receptor antagonist naloxone could completely block 030418-induced antinociception, while both the μ-opioid receptor antagonist β-FNA and the κ-opioid receptor antagonist nor-BNI attenuated 030418-induced antinociception. In contrast, the ORL1 receptor antagonist J-113397 enhanced the antinociceptive effect of 030418. Additionally, chronic treatment with 030418 resulted in a dramatic development of tolerance that could not be effectively prevented by J-113397. In guinea pig ileum preparation, the existing action of 030418 could be removed with difficulty after prolonged washing.
The compound 030418 is a novel agonist of opioid receptors with high efficiency, long-lasting effect and liability to tolerance, which may be closely correlated with the methyl group at the N(17) position and the high hydrophobicity of the C(7)-thiophene group in its chemical structure.
研究 N-甲基-7α-[(R)-1-羟基-1-甲基-3-(噻吩-3-基)-丙基]-6,14-内-乙叉基四氢诺罗啡(030418)对痛觉的抑制作用及其产生耐受的可能药理学机制,030418 是噻吩啡的衍生物。
采用 CHO-μ、CHO-κ、CHO-δ 和 CHO-ORL1 细胞膜受体结合和鸟苷 5'-O-(3-[(35)S]硫代)三磷酸([(35)S]GTPγS)测定 030418 的结合亲和力和效能。采用热痛觉试验在小鼠中评价 030418 的镇痛活性及其产生耐受的情况。采用体内药理学拮抗剂阻断和体外组织制剂进一步研究 030418 对阿片受体的影响。
该化合物 030418 对所有阿片受体亚型均显示出高的亲和力,其 Ki 值均在纳摩尔范围内。在 [(35)S]GTPγS 结合试验中,030418 对 μ、κ、δ 受体和 ORL1 受体的最大刺激分别为 89%、86%、67%和 91%。在热板试验中,030418 的镇痛作用比吗啡更强、持续时间更长。非选择性阿片受体拮抗剂纳洛酮可完全阻断 030418 引起的镇痛作用,而 μ 阿片受体拮抗剂 β-FNA 和 κ 阿片受体拮抗剂 nor-BNI 则减弱了 030418 引起的镇痛作用。相反,ORL1 受体拮抗剂 J-113397 增强了 030418 的镇痛作用。此外,030418 慢性治疗导致产生明显的耐受,而 J-113397 不能有效预防这种耐受。在豚鼠回肠制剂中,030418 的现有作用在长时间洗涤后很难消除。
化合物 030418 是一种新型阿片受体激动剂,具有高效、长效和易产生耐受的特点,这可能与它化学结构中 N(17)位的甲基和 C(7)-噻吩基的高疏水性密切相关。